The lung-restricted marker napsin a is highly expressed in clear cell carcinomas of the ovary

American Journal of Clinical Pathology

Volumn 142, Issue 6, 2014, Pages 830-836

  Kandalaft, Patricia L ^a   Gown, Allen M ^a   Isacson, Christina ^b  

^a PHENOPATH LABORATORIES   (United States)

^b CellNetix Pathology   (United States)

Author keywords

Immunohistochemistry; Napsin A; Ovarian clear cell carcinoma

Indexed keywords

ASPARTIC PROTEINASE; ESTROGEN RECEPTOR; NAPSIN A; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR PAX8; TUMOR MARKER; UNCLASSIFIED DRUG; WT1 PROTEIN; NAPSA PROTEIN, HUMAN;

ARTICLE; CANCER GRADING; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; COMPARATIVE STUDY; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA, CLEAR CELL; BIOSYNTHESIS; CARCINOMA, ENDOMETRIOID; DIFFERENTIAL DIAGNOSIS; METABOLISM; OVARIAN NEOPLASMS; RETROSPECTIVE STUDY;

ADENOCARCINOMA, CLEAR CELL; ASPARTIC ACID ENDOPEPTIDASES; CARCINOMA, ENDOMETRIOID; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84922274304     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP8WO2EOIAHSOF     Document Type: Article

References (33)

1. Turner BM, Cagle PT, Sainz IM, et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136:163-171.
2. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20-25.
3. Ye J, Findeis-Hosey JJ, Yang Q, et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol. 2011;19:313-317.
4. Kadivar M, Boozari B. Applications and limitations of immunohistochemical expression of "napsin-A" in distinguishing lung adenocarcinoma from adenocarcinomas of other organs. Appl Immunohistochem Mol Morphol. 2013;21:191-195.
5. Ye J, Hameed O, Findeis-Hosey JJ, et al. Diagnostic utility of PAX8, TTF-1 and napsin A for discriminating metastatic carcinoma from primary adenocarcinoma of the lung. Biotech Histochem. 2012;87:30-34.
6. Ballard M, Sangoi A, McKenney JK, et al. Napsin A staining in adrenal cortical neoplasms: comment on napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2013;137:883.
7. Kandalaft PL, Isacson C, Gown AM. The lung-restricted maker napsin A is highly expressed in clear cell carcinomas of the ovary. Mod Pathol. 2012;25(suppl 2):279A.
8. Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC; 2003.
9. Pectasides D, Pectasides E, Psyrri A, et al. Treatment issues in clear cell carcinoma of the ovary: A different entity? Oncologist. 2006;11:1089-1094.
10. Chiu MH, Gilks CB, Cooper K, et al. Identifying Lynch syndrome in patients with ovarian carcinoma: The significance of tumor subtype. Adv Anat Pathol. 2013;20:378-386.
11. Kurman RJ, Shih I-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer: shifting the paradigm. Hum Pathol. 2011;42:918-931.
12. DeLair D, Oliva E, Köbel M, et al. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: A study of 155 cases. Am J Surg Pathol. 2011;35:36-44.
13. Kaku T, Ogawa S, Kawano Y, et al. Histological classification of ovarian cancer. Med Electron Microsc. 2003;36:9-17.
14. Soslow RA. Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol. 2008;27:161-174.
15. Sangoi AR, Soslow RA, Teng NN, et al. Ovarian clear cell carcinoma with papillary features: A potential mimic of serous tumor of low malignant potential. Am J Surg Pathol. 2008;32:269-274.
16. McCluggage WG, Lyness RW, Atkinson RJ, et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol. 2002;55:27-31.
17. Chew I, Soslow RA, Park KJ. Morphologic changes in ovarian carcinoma after neoadjuvant chemotherapy: report of a case showing extensive clear cell changes mimicking clear cell carcinoma. Int J Gynecol Pathol. 2009;28:442-446.
18. Köbel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: A transcanadian study. Am J Surg Pathol. 2010;34:984-993.
19. Ordóñez NG. Value of PAX 8 immunostaining in tumor diagnosis: A review and update. Adv Anat Pathol. 2012;19:140-151.
20. Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: A comprehensive immunohistochemical study. Mod Pathol. 2011;24:751-764.
21. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816-826.
22. Köbel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33:14-21.
23. Kubba LA, McCluggage WG, Liu J, et al. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol. 2008;21:485-490.
24. Zhang PJ, Gao HG, Pasha TL, et al. TTF0-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol. 2009;28:10-18.
25. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2006;19:83-89.
26. Tuschiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinomas: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503-2512.
27. DeLair D, Han G, Irving JA, et al. HNF-1b in ovarian carcinomas with serous and clear cell change. Int J Gynecol Pathol. 2013;32:541-546.
28. Fadare O, Desouki MM, Gwin K, et al. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol. 2014;38:189-196.
29. Fadare O, Zhao C, Quick CM, et al. Comparative analysis of napsin A, AMACR, and hepatocyte nuclear factor 1b as diagnostic markers of ovarian clear cell carcinoma: An immunohistochemical study of 260 ovarian tumors. Mod Pathol. 2014;27(suppl 2):282A.
30. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422-6430.
31. Pan Z, Grizzle W, Hameed O. Significant variation of immunohistochemical marker expression in paired primary and metastatic clear cell renal cell carcinomas. Am J Clin Pathol. 2013;140:410-418.
32. Ozcan A, de la Roza G, Ro JY, et al. PAX2 and PAX8 expression in primary and metastatic renal tumors: A comprehensive comparison. Arch Pathol Lab Med. 2012;136:1541-1551.
33. Gokden N, Gokden M, Phan DC, et al. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: An immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol. 2008;32:1462-1467.